Cubist Pharmaceuticals has appointed Dr Jennifer Jackson as its new Senior Vice President of Regulatory Affairs.
Dr Jackson will oversee all aspects of Cubist’s Regulatory Affairs, providing oversight for all regulatory matters, reporting to Dr Steve Gilman, the company’s Executive Vice President of R&D and CSO.
Dr Gilman said: “Jennifer’s extensive international experience, collaborative nature, and focus on disciplined execution will help us as we advance our exciting pipeline in the years ahead.”
Dr Jackson joins Cubist from Biogen Idec Hemophilia, where she worked as vice president of Regulatory Affairs and Clinical Compliance. She has also worked at Vertex Pharmaceuticals and Bristol-Myers Squibb.
Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialisation of pharmaceutical products that address the unmet medical needs in acute care.